healthcare
healthcare Articles
Plus Therapeutics shares rallied on Tuesday after an FDA update on its treatment of patients with recurrent glioblastoma.
Published:
Three U.S. COVID-19 vaccine trials are now in Phase 3 studies. All three appear to have some serious benefits, but none are approved yet.
Published:
The prize for Nestle in its acquisition of Aimmune Therapeutics is Palforzia, the world’s first treatment for a food allergy.
Published:
Health care services provider GoodRX has filed the SEC for its initial public offering.
Published:
Akcea Therapeutics stock jumped on Monday after it was announced that Ionis Pharmaceuticals would be acquiring all of its outstanding shares.
Published:
These five dividend-paying large-cap pharmaceutical stocks look like outstanding ideas for nervous investors looking for income and a degree of safety. They have come way in from their 52-week...
Published:
Fluidigm made a splash with the markets on Wednesday morning after the company announced a critical update from the FDA in regards to its COVID-19 test.
Published:
The August 14 short interest data has been compared with the previous report, and short interest in most of these selected biotech stocks decreased.
Published:
Medtronic reported better than expected quarterly results before the markets opened on Tuesday.
Published:
Has the COVID-19 pandemic discouraged bystanders from helping a person who may be suffering from a heart attack?
Published:
Cancer Genetics shares more than doubled on Monday after the company announced a merger with StemoniX.
Published:
Onconova Therapeutics stock was absolutely crushed to start out the week after the company reported results from its late-stage cancer study.
Published:
Pfizer and BioNTech provided an update for their coronavirus vaccine that is currently in the late stages of development and testing.
Published:
After Momenta Pharmaceuticals announced that it would be acquired by pharmaceutical giant Johnson & Johnson, the biotechnology company's shares soared on Wednesday.
Published:
The FDA has come down on an investigational treatment for moderately to severely active from Gilead Sciences and Galapagos.
Published: